The whitepaper analyzes the literature and clinical experience behind the ON-Q Pain Relief System and Pacira’s Exparel.
Frost & Sullivan identified three criteria that establish ON-Q as the preferred choice of clinicians over Exparel for postoperative pain management: greater economic value across the entire postoperative period, proven clinical effectiveness specific to individual patient needs and safety and predictability rooted in evidence. The full paper is scheduled for release in April 2014.
I-Flow is the manufacturer of the ON-Q Pain Relief System.
More Articles on Supply Chain:
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
